p300/CBP degrader ADC / Novartis - LARVOL DELTA

Targeted degradation of p300 and CBP via antibody-drug conjugate in prostate cancer cells (AACR 2026) - "A second conjugate, anti-PSMA-BRSD056, led to 77% tumor growth inhibition of LnCaP tumors. Our work shows the potential of developing highly potent p300/CBP degraders that can be specifically vectorized to prostate cancer tumors, which may improve efficacy and tolerability in challenging disease settings."

ADC • Late-breaking abstract • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR • CD276 • CRBN • FOXA1 • MYC